Search

Your search keyword '"Dendukuri, Nandini"' showing total 680 results
Start Over Author "Dendukuri, Nandini"
680 results on '"Dendukuri, Nandini"'

6. Clinical Outcomes of Rapid Respiratory Virus Testing in Emergency Departments

Author

Schober, Tilmann, primary, Wong, Kimberly, additional, DeLisle, Gaëlle, additional, Caya, Chelsea, additional, Brendish, Nathan J., additional, Clark, Tristan W., additional, Dendukuri, Nandini, additional, Doan, Quynh, additional, Fontela, Patricia S., additional, Gore, Genevieve C., additional, Li, Patricia, additional, McGeer, Allison J., additional, Noël, Kim Chloe, additional, Robinson, Joan L., additional, Suarthana, Eva, additional, and Papenburg, Jesse, additional

Published
2024
Full Text
View/download PDF

8. Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial

Author

Jolicoeur, E. Marc, Dendukuri, Nandini, Belisle, Patrick, Range, Grégoire, Souteyrand, Geraud, Bouisset, Frédéric, Zemour, Gilles, Delarche, Nicolas, Harbaoui, Brahim, Schampaert, Erick, Kouz, Simon, Cayla, Guillaume, Roubille, François, Boueri, Ziad, Mansour, Samer, Marcaggi, Xavier, Tardif, Jean-Claude, McGillion, Michael, Tanguay, Jean-François, Brophy, James, Yu, Cheol Woong, Berry, Colin, Carrick, David, Høfsten, Dan Eik, Engstrøm, Thomas, Kober, Lars, Kelbæk, Henning, and Belle, Loic

Published
2020
Full Text
View/download PDF

16. Reproducibility of Interferon Gamma (IFN-γ) Release Assays. A Systematic Review

Author

Tagmouti, Saloua, Slater, Madeline, Benedetti, Andrea, Kik, Sandra V, Banaei, Niaz, Cattamanchi, Adithya, Metcalfe, John, Dowdy, David, van Zyl Smit, Richard, Dendukuri, Nandini, Pai, Madhukar, and Denkinger, Claudia

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Rare Diseases, Infection, Good Health and Well Being, Humans, Interferon-gamma, Reproducibility of Results, Tuberculin, Tuberculosis, IFN-γ release assays, diagnostics, reproducibility, tuberculosis, Cardiovascular medicine and haematology, Clinical sciences
Abstract

RationaleInterferon gamma (IFN-γ) release assays for latent tuberculosis infection result in a larger-than-expected number of conversions and reversions in occupational screening programs, and reproducibility of test results is a concern.ObjectivesKnowledge of the relative contribution and extent of the individual sources of variability (immunological, preanalytical, or analytical) could help optimize testing protocols.MethodsWe performed a systematic review of studies published by October 2013 on all potential sources of variability of commercial IFN-γ release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB). The included studies assessed test variability under identical conditions and under different conditions (the latter both overall and stratified by individual sources of variability). Linear mixed effects models were used to estimate within-subject SD.Measurements and main resultsWe identified a total of 26 articles, including 7 studies analyzing variability under the same conditions, 10 studies analyzing variability with repeat testing over time under different conditions, and 19 studies reporting individual sources of variability. Most data were on QuantiFERON (only three studies on T-SPOT.TB). A considerable number of conversions and reversions were seen around the manufacturer-recommended cut-point. The estimated range of variability of IFN-γ response in QuantiFERON under identical conditions was ±0.47 IU/ml (coefficient of variation, 13%) and ±0.26 IU/ml (30%) for individuals with an initial IFN-γ response in the borderline range (0.25-0.80 IU/ml). The estimated range of variability in noncontrolled settings was substantially larger (±1.4 IU/ml; 60%). Blood volume inoculated into QuantiFERON tubes and preanalytic delay were identified as key sources of variability.ConclusionsThis systematic review shows substantial variability with repeat IFN-γ release assays testing even under identical conditions, suggesting that reversions and conversions around the existing cut-point should be interpreted with caution.

Published
2014

18. COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)—a Randomized Controlled Clinical Trial.

Author

Le, Michelle, Khoury, Lauren, Lu, Yang, Prosty, Connor, Cormier, Maxime, Cheng, Mathew P, Fowler, Robert, Murthy, Srinivas, Tsang, Jennifer L Y, Ben-Shoshan, Moshe, Rahme, Elham, Golchi, Shirin, Dendukuri, Nandini, Lee, Todd C, and Netchiporouk, Elena

Subjects
URTICARIA, CLINICAL trials, RANDOMIZED controlled trials, OMALIZUMAB, COVID-19, CORONAVIRUS diseases
Abstract

Background Omalizumab is an anti-immunoglobulin E monoclonal antibody used to treat moderate to severe chronic idiopathic urticaria, asthma, and nasal polyps. Recent research suggested that omalizumab may enhance the innate antiviral response and have anti-inflammatory properties. Objective We aimed to investigate the efficacy and safety of omalizumab in adults hospitalized for coronavirus disease 2019 (COVID-19) pneumonia. Methods This was a phase II randomized, double blind, placebo-controlled trial comparing omalizumab with placebo (in addition to standard of care) in hospitalized patients with COVID-19. The primary endpoint was the composite of mechanical ventilation and/or death at day 14. Secondary endpoints included all-cause mortality at day 28, time to clinical improvement, and duration of hospitalization. Results Of 41 patients recruited, 40 were randomized (20 received the study drug and 20 placebo). The median age of the patients was 74 years and 55.0% were male. Omalizumab was associated with a 92.6% posterior probability of a reduction in mechanical ventilation and death on day 14 with an adjusted odds ratio of 0.11 (95% credible interval 0.002-2.05). Omalizumab was also associated with a 75.9% posterior probability of reduced all-cause mortality on day 28 with an adjusted odds ratio of 0.49 (95% credible interval, 0.06-3.90). No statistically significant differences were found for the time to clinical improvement and duration of hospitalization. Numerically fewer adverse events were reported in the omalizumab group and there were no drug-related serious adverse events. Conclusions These results suggest that omalizumab could prove protective against death and mechanical ventilation in hospitalized patients with COVID-19. This study could also support the development of a phase III trial program investigating the antiviral and anti-inflammatory effect of omalizumab for severe respiratory viral illnesses requiring hospital admission. ClinicalTrials.gov ID: NCT04720612 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Evaluating the Accuracy and Economic Value of a New Test in the Absence of a Perfect Reference Test

Author

Xie, Xuanqian, Sinclair, Alison, and Dendukuri, Nandini

Abstract

Background: "Streptococcus pneumoniae" (SP) pneumonia is often treated empirically as diagnosis is challenging because of the lack of a perfect test. Using BinaxNOW-SP, a urinary antigen test, as an add-on to standard cultures may not only increase diagnostic yield but also increase costs. Objective: To estimate the sensitivity and specificity of BinaxNOW-SP and subsequently estimate the cost-effectiveness of adding BinaxNOW-SP to the diagnostic work-up. Design: We fit a Bayesian latent-class meta-analysis model to obtain estimates of BinaxNOW-SP accuracy that adjust for the imperfect accuracy of culture. Meta-analysis results were combined with information on prevalence of SP pneumonia to estimate the number of patients who are correctly classified under competing diagnostic strategies. Taking into consideration the cost of antibiotics, we determined the incremental cost of adding BinaxNOW-SP to the work-up per case correctly diagnosed. Results: The BinaxNOW-SP test had a pooled sensitivity of 0.74 (95% credible interval [CrI], 0.67-0.83) and a pooled specificity of 0.96 (95% CrI, 0.92-0.99). An overall increase in diagnostic accuracy of 6.2% due to the addition of BinaxNOW-SP corresponded to an incremental cost per case correctly classified of $582 Canadian dollars. Conclusions: The methods we have described allow us to evaluate the accuracy and economic value of a new test in the absence of a perfect reference test using an evidence-based approach.

Published
2017
Full Text
View/download PDF

33. International Survey on Determinants of Antibiotic Duration and Discontinuation in Pediatric Critically Ill Patients

Author

Noël, Kim C., Papenburg, Jesse, Lacroix, Jacques, Quach, Caroline, O’Donnell, Shauna, Gonzales, Milagros, Willson, Douglas F., Gilfoyle, Elaine, McNally, James D., Reynolds, Steven, Kazzaz, Yasser, Kawaguchi, Atsushi, Sato, Masanori, Kongkiattikul, Lalida, Leteurtre, Stéphane, Dubos, François, Karaca, Yasemin, Chiusolo, Fabrizio, Piva, Jefferson, Dendukuri, Nandini, and Fontela, Patricia S.

Published
2020
Full Text
View/download PDF

35. IN-HOSPITAL AND 1-YEAR OUTCOMES FOLLOWING ANTEGRADE-ONLY VERSUS RETROGRADE CHRONIC TOTAL OCCLUSION: INSIGHTS FROM THE CANADIAN CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION REGISTRY

Author

Verreault-Julien, Louis, primary, Dendukuri, Nandini, additional, Jahan, Israth, additional, Mansour, Samer, additional, Matteau, Alexis, additional, Wijeysundera, Harindra, additional, Fung, Anthony Y., additional, Robinson, Simon, additional, Paradis, Jean-Michel, additional, and Nguyen, Can Manh, additional

Published
2023
Full Text
View/download PDF

39. P11.19: System-Level Barriers to Living Donor Kidney Transplantation: A Cross-Sectional Survey Study of Health Professionals

Author

Sandal, Shaifali, primary, Schiller, Ian, additional, Dendukuri, Nandini, additional, Robert, Jorane-Tiana, additional, Katergi, Khaled, additional, Alam, Ahsan, additional, Cantarovich, Marcelo, additional, Fiore, Julio F, additional, Suri, Rita, additional, Landsberg, David, additional, Weber, Catherine, additional, and Fortin, Marie-Chantal, additional

Published
2022
Full Text
View/download PDF

49. Additional file 1 of Bayesian latent class analysis produced diagnostic accuracy estimates that were more interpretable than composite reference standards for extrapulmonary tuberculosis tests

Author

MacLean, Emily L., Kohli, Mikashmi, Köppel, Lisa, Schiller, Ian, Sharma, Surendra K., Pai, Madhukar, Denkinger, Claudia M., and Dendukuri, Nandini

Abstract

Additional file 1: Supplemental Figure S1. Pairwise residual correlation plots for tests run on A) lymph node, B) CSF, and C) pleural fluid. Test pair 1: culture and Xpert; 2: culture and smear microscopy; 3: culture and cytopathology/histopathology or ADA; 4: Xpert and smear microscopy; 5: Xpert and cytopathology/histopathology or ADA; 6: smear microscopy and cytopathology/histopathology or ADA. ADA – adenosine deaminase; CSF – cerebral spinal fluid; TB – tuberculosis. Supplemental Figure S2. Density plots. For each of the three models (one per form of extrapulmonary TB), density plots were generated for each parameter of interest. For test result parameters specificity, C, and sensitivity, S, the indices 1, …,4 indicate culture, Xpert, smear microscopy, and ADA or cytopathology/histopathology. Supplementary Table S1. Probabilities of the four latent classes, for each form of extrapulmonary TB as estimated by Bayesian latent class analysis. Supplementary Table S2. Diagnostic accuracies of tests for each form of extrapulmonary TB by latent class analysis. Supplementary Table S3. Prevalence of each form of extrapulmonary TB as estimated by the two-class latent class model

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results